RxDoctor Payments Data

Mary Mattheos, MD

Internal Medicine · Lindenhurst, NYNPI 1609977719

Payments from drug & device makers

$7,223in general payments, 2019–2025

Across 363 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$636
  • AstraZeneca$634
  • Pfizer$634
  • Novo Nordisk$506
  • Boehringer Ingelheim$471
  • GSK$440
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,217100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,223 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$557,357
Medicare patients
559
Services billed
15,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$166,701
MounjaroTirzepatide48$80,833
EliquisApixaban51$63,232
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$40,632
RybelsusSemaglutide22$38,207
ProliaDenosumab22$36,809
JanuviaSitagliptin Phosphate22$26,630
VivitrolNaltrexone Microspheres11$18,094
JardianceEmpagliflozin13$15,611
Tresiba Flextouch U-200Insulin Degludec11$13,579
Xigduo XrDapaglifloz Propaned/Metformin14$12,520
Breo ElliptaFluticasone/Vilanterol15$12,165
VascepaIcosapent Ethyl16$10,821
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$5,498
Risedronate Sodium57$4,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$506$204,909140 claims
Lilly USA, LLCMounjaro$186$80,83348 claims
PfizerEliquis$634$63,23251 claims
GSKTrelegy Ellipta, Breo Ellipta$440$52,79744 claims
AmgenProlia$429$36,80922 claims
MerckJanuvia$53$26,63022 claims
Boehringer IngelheimJardiance$471$15,61113 claims
AbbVieSynthroid$636$3,99169 claims
ANI Pharmaceuticals, Inc.Valsartan$24$2,66185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Lindenhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →